Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial

2016896 citationserratumhybrid Open Access

Authors

David Fitchett · University of Toronto

Bernard Zinman · Mount Sinai Hospital

Christoph Wanner · Universitätsklinikum Würzburg

John M. Lachin · George Washington University

Stefan Hantel · Boehringer Ingelheim (Germany)

Afshin Salsali · Boehringer Ingelheim (United States)

Odd Erik Johansen

Abstract

In patients with type 2 diabetes and high cardiovascular risk, empagliflozin reduced heart failure hospitalization and cardiovascular death, with a consistent benefit in patients with and without baseline heart failure.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 37, Issue 19, pp. 1526-1534

DOI: 10.1093/eurheartj/ehv728

Field-Weighted Citation Impact: 118.14